drugset / Trial / NCT03159052
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to obtain information on efficacy and safety of SHR3824 over 24 weeks and 52 weeks in Chinese patients with Type 2 Diabetes. This will be done by comparing the effect of SHR3824 to placebo when given in oral doses.
Timeline
- Start
- 2017-06
- Primary completion
- 2018-10
- Completion
- 2019-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Henagliflozin | Small molecule | 5 mg | Oral |
| Subject | Henagliflozin | Small molecule | 10 mg | Oral |